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We thank Simpa S Salami and colleagues for raising three important issues. 
First, the primary role of a triage test is to rule out clinically significant prostate cancer and 
by doing so help the patient avoid an unnecessary biopsy. If the MRI does reveal an 
abnormality with a high probability of prostate cancer it should be targeted. The PROMIS1 
study did not address the issue of targeting because it was a blinded study. Other studies have 
investigated this and several others are currently recruiting.2 
Second, we disagree that the performance of multi parametric MRI parallels that of prostate-
specific antigen. In PROMIS, prostate-specific antigen did not contribute to the prediction of 
clinically significant prostate cancer. By contrast, the MRI-derived Likert score was closely 
correlated with clinically significant prostate cancer. 
Third, we agree that our prevailing assumptions about clinically significant prostate cancer 
should be questioned. Nonetheless, increasing evidence suggests that lesions with a Gleason 
score of 6 do not have hallmarks of malignancy3 and that many tumours with a Gleason score 
of 3 + 4 = 7 do well without immediate treatment,4 whether diagnosed initially or even if 
missed by a transrectal ultrasound-guided prostate biopsy.5 One of the most striking attributes 
of MRI within PROMIS was the complete absence of any misclassification of cancers with 
Gleason grade group III, IV, or V. 
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